Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
03/2012
03/07/2012CN101015501B Injection composition of fat milk, amino acid and glucose packed with three-cavity bag and preparing method thereof
03/06/2012US8129545 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
03/06/2012US8129541 5-phenylthiazole derivatives and use as PI3 kinase inhibitors
03/06/2012US8129537 Compounds as PDE IV and TNF inhibitors
03/06/2012US8129381 Caspase inhibitors and uses thereof
03/06/2012US8129372 Compounds having NPY Y5 receptor antagonistic activity
03/06/2012US8129360 Administration of an agent produced from phosphatidylserine (PS), lyso-phosphatidylserine or/and a physiologically acceptable salt thereof in combination with additive selected from a group comprising antioxidants, essential fatty acids, mineral substances, amino acids, mood-lifters, phospholipids
03/06/2012US8129343 Acylated GLP-1 compounds
03/06/2012US8129339 Microencapsulation and sustained release of biologically active polypeptides
03/06/2012US8129331 Ang-2 inhibitor peptides; use treating tumors, eye disorders, bone disorders, psoriasis; angiogenesis inhibitors; amino acid sequence WDPWT
03/06/2012US8129132 Using glutamate decarboxylase concentration as diagnostic indicator of autoimmune and connective tissue disorders
03/06/2012CA2613041C Agent for improving insulin resistance
03/06/2012CA2523245C Indole acetic acid derivatives and their use as pharmaceutical agents
03/06/2012CA2514539C Process for producing coated preparation
03/06/2012CA2487734C Treatment with cytokines for alzheimer's disease
03/06/2012CA2486055C Amines that inhibit a mammalian anandamide transporter, and methods of use thereof
03/06/2012CA2485532C Process for the preparation of 2-methyl piperazine derivatives
03/06/2012CA2476056C Novel 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same
03/06/2012CA2446705C Compositions of quinoxaline-based therapeutic agents and fatty acids having enhanced pharmacokinetic characteristics
03/06/2012CA2442694C Osteoprotegerin in milk
03/06/2012CA2290944C Pgc-1, a novel brown fat ppar.gamma. coactivator
03/03/2012CA2751306A1 Methods for controlling blood-glucose levels in insulin-requiring subjects
03/01/2012WO2012027710A2 Compounds that modulate intracellular calcium
03/01/2012WO2012027695A1 Methods and compositions for preventing or treating obesity
03/01/2012WO2012027601A2 Methods targeting mir-33 micrornas for regulating lipid metabolism
03/01/2012WO2012027555A2 Glycated cd59 peptides, their preparation, and uses thereof
03/01/2012WO2012027482A2 Compounds, compositions and methods related to ppar antagonists
03/01/2012WO2012026748A2 Pharmaceutical composition containing melastoma sanguineum extracts or fractions thereof as active ingredients for preventing and treating diabetic complications
03/01/2012WO2012026495A1 Novel hydantoin derivative and medicinal agent comprising same as active ingredient
03/01/2012WO2012025877A1 Proline sulfonamide derivatives as orexin receptor antagonists
03/01/2012WO2012025857A1 Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
03/01/2012WO2011149713A3 Compositions of nutrition supplementation for nutritional deficiencies and method of use therefore
03/01/2012WO2011005811A8 Combination therapy for the treatment of diabetes
03/01/2012US20120053451 Methods and systems for prolonged localization of drug delivery
03/01/2012US20120053242 Compositions rich in omega-3 fatty acids with a low content in phytanic acid
03/01/2012US20120053241 Aqueous nanoemulsion composition containing conjugated linoleic acid
03/01/2012US20120053240 Method of Administering beta-hydroxy-beta-methylbutyrate (HMB)
03/01/2012US20120053235 Dihydromyricetin as an IKK-beta inhibitor used for treatment of arthritis, cancer and autoimmune conditions, and other diseases or disorders
03/01/2012US20120053229 Regulation of MIR-33 MicroRNAs in the Treatment of Cholesterol-Related Disorders
03/01/2012US20120053227 miR-33 INHIBITORS AND USES THEREOF
03/01/2012US20120053222 Novel Metabolic Disease Therapy
03/01/2012US20120053210 Compounds that modulate intracellular calcium
03/01/2012US20120053208 Curcumin Analogs as Dual JAK2/STAT3 Inhibitors and Methods of Making and Using the Same
03/01/2012US20120053200 Bace 2 inhibitors
03/01/2012US20120053197 Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
03/01/2012US20120053191 Oxidated derivatives of triazolylpurines useful as ligands of the adenosine a2a receptor and their use as medicaments
03/01/2012US20120053186 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
03/01/2012US20120053184 Salts of 3-(1h-ind0l-3-yl)-4-[2-(4-methyl-piperazin-i-yl)-quinazolin-4-yl]-pyrrole-2, 5-di one
03/01/2012US20120053180 Cyclohexane analogues as gpr119 agonists
03/01/2012US20120053173 Heterocyclic compound
03/01/2012US20120053172 Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
03/01/2012US20120053168 Fused benzoazepines as neuronal nicotinic acetylcholine receptor ligands
03/01/2012US20120053167 Triazine Derivatives as Kinase Inhibitors
03/01/2012US20120053164 Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd
03/01/2012US20120053163 Steroids as Agonists for FXR
03/01/2012US20120053156 Compositions and methods for loop diuretics with consistent bioavailability
03/01/2012US20120053143 Triacetyl-3-hydroxyphenyladenosine and its use for regulating blood fat
03/01/2012US20120053119 Therapeutic method for increasing pancreatic beta cell mass
03/01/2012US20120053118 Methods for affecting body composition using amylin agonists
03/01/2012US20120053113 MANUFACTURE OF INTER-ALPHA-INHIBITOR (IaIp) FROM PLASMA
03/01/2012US20120052138 Composition comprising green tea extract
03/01/2012US20120052137 Weight loss formulation
03/01/2012US20120052135 Phosphate Adsorbent
03/01/2012US20120052132 Compositions and methods for treatment of body weight conditions
03/01/2012US20120052130 Gpr 119 modulators
03/01/2012US20120052126 Nanoemulsions Containing Antioxidants And Other Health-Promoting Compounds
03/01/2012US20120052119 Nanoencapsulated delta-9-tetrahydrocannabinol
03/01/2012US20120052098 Liquid ganaxolone formulations and methods for the making and use thereof
03/01/2012US20120052096 Novel dioxo-imidazolidine derivatives, which inhibit the enzyme soat-1, and pharmaceutical and cosmetic compositions containing them
03/01/2012US20120052088 Pneumococcal vaccine and uses thereof
03/01/2012US20120052070 Compositions and methods of use for binding molecules to dickkopf-1 or dickkopf-4 or both
03/01/2012US20120052069 Fgf21 mutants and uses thereof
03/01/2012US20120052056 Composition for improving blood circulation containing fermented tea, and pharmaceutical and health-food compositions comprising the same
03/01/2012US20120052053 Compositions and methods for the treatment of altered alpha-synuclein function
03/01/2012US20120052049 Systemic, Allogenic Stem Cell Therapies For Treatment of Diseases in Animals
03/01/2012US20120052005 Combination therapy to improve drug efficiency
03/01/2012DE102010036213A1 Use of peracylated hexoses or peracylated pentoses for improving or normalizing the energy and constructive metabolism of body cells, preferably cells of the central nervous system, muscles and liver
03/01/2012CA2809830A1 Compounds that modulate intracellular calcium
03/01/2012CA2807965A1 Methods for treating antipsychotic-induced weight gain
03/01/2012CA2807000A1 Proline sulfonamide derivatives as orexin receptor antagonists
02/2012
02/29/2012EP2423223A1 Novel exendin variant and conjugate thereof
02/29/2012EP2423203A1 Crystal of benzoxazinone compound
02/29/2012EP2423194A1 NOVEL THYROID HORMONE beta RECEPTOR AGONIST
02/29/2012EP2423176A1 Carboxylic acid compound
02/29/2012EP2422789A1 Injectable coposition comprising sodium deoxycholate
02/29/2012EP2421850A1 3 -azabicyclo [4.1.0]heptanes used as orexin antagonists
02/29/2012EP2421836A1 2-aryl imidazoline derivatives
02/29/2012EP2421611A1 Fgfr1c antibody combinations
02/29/2012EP2421548A1 Use of (hexenoyl trans-3)hgrf(l-44)nh2 and simvastatin in combination therapy
02/29/2012EP2421524A2 Chemosensory receptor ligand-based therapies
02/29/2012EP2421373A1 Colon lavage system
02/29/2012EP2176255B1 Andrographolide derivatives and use thereof in manufacture of medicaments
02/29/2012EP2123649B1 3-pyrrolo-cyclohexylene-2-dihydro-indolinone derivatives and uses thereof
02/29/2012EP2094643B1 N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
02/29/2012EP1669350B1 Piperidine derivatives
02/29/2012EP1532153B1 Azepinoindole and pyridoindole derivatives as pharmaceutical agents
02/29/2012EP1248604B2 Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
02/29/2012CN102365290A Method for producing sugar composition containing definite amount of target hexose and having sugar composition ratio different from starting sugar material, and use of sugar composition thus produced
02/29/2012CN102365275A Carboxamide compounds and methods for using the same
02/29/2012CN102365272A Key intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof
1 ... 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 ... 1298